The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term survival outcomes with immune checkpoint inhibitors (ICI) in metastatic uveal melanoma (MUM).
 
Cha Len Lee
No Relationships to Disclose
 
Naomi Walsh
No Relationships to Disclose
 
Fergus Keane
No Relationships to Disclose
 
Emer Lynch
No Relationships to Disclose
 
Tadhg Reddan
No Relationships to Disclose
 
Helen Craig
No Relationships to Disclose
 
Aileen O'Meara
No Relationships to Disclose
 
Deirdre Smith
Employment - AstraZeneca
Leadership - AstraZeneca
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca
 
Valerie O'Neill
No Relationships to Disclose
 
Noel Horgan
No Relationships to Disclose
 
Susan Kennedy
No Relationships to Disclose
 
Giuseppe Gullo
Employment - Regeneron
Leadership - Regeneron
Consulting or Advisory Role - Regeneron
Speakers' Bureau - Regeneron
 
John Crown
Employment - OncoMark
Stock and Other Ownership Interests - OncoMark
Honoraria - MSD Oncology; Novartis Ireland Ltd.; Pfizer; Roche
Consulting or Advisory Role - G1 Therapeutics; MSD Oncology; Novartis Ireland Ltd.; Pfizer; Puma Biotechnology; Roche
Speakers' Bureau - Pfizer
Research Funding - Boehringer Ingelheim (Inst); Eisai (Inst); Puma Biotechnology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - WO2020011770 (A1) - A method of predicting response to treatment in cancer patients
Travel, Accommodations, Expenses - Abbvie; Daiichi Sankyo Europe GmbH; MSD; Novartis Ireland Ltd.; Pfizer; Roche